Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study

Puntos clave

• The research aims to identify optimal conditions for rechallenging immune-checkpoint inhibitors in metastatic clear-cell renal cell carcinoma.
• Analyzed global real-world data on immune-checkpoint inhibitor rechallenge outcomes.
• Evaluated treatment intervals and their impact on response rates.
• Recommended prospective trials to explore timing as a surrogate marker.
• Patients with longer intervals (≥6 months) between immune-checkpoint inhibitor treatments showed improved outcomes.
• Timing of treatment rechallenge appears to be a significant factor in efficacy.